Works Cited: Information Hub

Brubaker, P. (2023, December 15). What is next in the evolution of GLP-1-based therapies for diabetes and obesity?. McGill Office for Science and Society. https://www.mcgill.ca/oss/article/medical-health-and-nutrition/what-next-evolution-glp-1-based-therapies-diabetes-and-obesity

Castro, R. (2022, June 29). GLP-1 agonists: Diabetes drugs and weight loss. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/expert-answers/byetta/faq-20057955

Centers for Disease Control and Prevention. (2020, July 10). National Health and Nutrition Examination Survey. Centers for Disease Control and Prevention. https://www.cdc.gov/nchs/about/factsheets/factsheet_nhanes.html

Centers for Disease Control and Prevention. (2022a, June 3). Defining adult overweight & obesity. Centers for Disease Control and Prevention. https://www.cdc.gov/obesity/basics/adult-defining.html

Centers for Disease Control and Prevention. (2022b, June 3). Defining adult overweight & obesity. Centers for Disease Control and Prevention. https://www.cdc.gov/obesity/basics/adult-defining.html

Collins, B. (2023, January 20). New weight loss drugs trending with billionaires and celebrities are about to enter more American homes. CNBC. https://www.cnbc.com/2023/01/20/trending-glp-1-weight-loss-drugs-are-shipping-to-more-american-homes.html

Diabetes UK. (2024, January 4). Our response to serious supply issues of drugs for people with type 2 diabetes. Diabetes UK. https://www.diabetes.org.uk/about-us/news-and-views/our-response-serious-supply-issues-drugs-people-living-type-2-diabetes

Dosing schedule for Saxenda®: Saxenda® (liraglutide) injection 3mg. Dosing Schedule for Saxenda® | Saxenda® (liraglutide) injection 3mg. (2024). https://www.saxenda.com/about-saxenda/dosing-schedule.html

Dunleavy, K. (2023, June 26). Ada: Novo Nordisk, Eli Lilly Show Progress for oral GLP-1 treatments for obesity. Fierce Pharma. https://www.fiercepharma.com/pharma/ada-novo-nordisk-eli-lilly-show-progress-oral-glp-1-treatments-obesity#:~:text=A%20phase%203%20study%20of,Novo’s%20injected%20GLP%2D1%20drugs

FDA. (2020, December 4). FDA approves Weight Management Drug. U.S. Food and Drug Administration. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-weight-management-drug-patients-aged-12-and-older

FDA. (2021, June 4). FDA approves new drug treatment for Chronic Weight Management, first since 2014. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014 

FDA. (2022, June 29). Compounding and the FDA: Q & A. U.S. Food and Drug Administration. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers 

FDA. (2023a, March 23). Drug compounding and drug shortages. U.S. Food and Drug Administration. https://www.fda.gov/drugs/human-drug-compounding/drug-compounding-and-drug-shortages 

FDA. (2023b, November 8). FDA approves new medication for chronic weight management. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management 

FDA. (2024a, January 10). Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss. U.S. Food and Drug Administration. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss 

FDA. (2024b, January 10). Medications containing semaglutide. U.S. Food and Drug Administration. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss 

Fornes, A., Huff, J., Pritchard, R. I., & Godfrey, M. (2022). Once-weekly semaglutide for Weight Management: A clinical review. Journal of Pharmacy Technology, 38(4), 239–246. https://doi.org/10.1177/87551225221092681 

Glass, R., & Foster, E. (n.d.). Transitional assistance programs in the GLP-1 market. IQVIA. https://www.iqvia.com/locations/united-states/blogs/2023/08/transitional-assistance-programs-in-the-glp1-market 

GLP-1 agonists. Cleveland Clinic. (2023, July 3). https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists 
GoodRx. (2023, June). Is compounded semaglutide safe? here’s what you should know. GoodRx. https://www.goodrx.com/classes/glp-1-agonists/compounded-semaglutide 

Gosala, S. (2024a, January 3). Webinar: GLP-1S & the AMP cap in the american rescue plan act. Truveris. https://truveris.com/glp1s-amp-cap-american-rescue-plan-act/ 

Gosala, S. (2024b, January 4). The impact of GLP-1 coverage and spend on pharmacy benefits costs. New. https://truveris.com/impact-glp1-coverage-spend-on-pharmacy-benefits/ 

Gosala, S. (2024c, January 4). The impact of GLP-1 coverage and spend on pharmacy benefits costs. Truveris. https://truveris.com/impact-glp1-coverage-spend-on-pharmacy-benefits/ 

Green, L., & Taddei-Allen, P. (2023). Shifting paradigms: Reframing coverage of Antiobesity Medications for plan sponsors. Journal of Managed Care & Specialty Pharmacy, 29(5), 564–568. https://doi.org/10.18553/jmcp.2023.29.5.564 

Han, S. H., Safeek, R., Ockerman, K., Trieu, N., Mars, P., Klenke, A., Furnas, H., & Sorice-Virk, S. (2023). Public interest in the off-label use of glucagon-like peptide 1 agonists (ozempic) for cosmetic weight loss: A google trends analysis. Aesthetic Surgery Journal, 44(1), 60–67. https://doi.org/10.1093/asj/sjad211 

Hughes, S., & Neumiller, J. J. (2020b). Oral semaglutide. Clinical Diabetes, 38(1), 109–111. https://doi.org/10.2337/cd19-0079

Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/nejmoa2206038 

Knudsen, L. B., & Lau, J. (2019). The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology, 10. https://doi.org/10.3389/fendo.2019.00155 

Krutika Amin, I. T., & 2023, A. (2023, August 17). How do prices of drugs for weight loss in the U.S. compare to peer nations’ prices? KFF. https://www.kff.org/health-costs/issue-brief/how-do-prices-of-drugs-for-weight-loss-in-the-u-s-compare-to-peer-nations-prices/ 

Kubala, J. (2023, November 30). How to get ozempic in person or online in 2024: What to know. Healthline. https://www.healthline.com/nutrition/how-to-get-ozempic 

Landi, H. (2023, May 9). Digital health companies making a long-term play to tackle metabolic health amid hype over $100B weight loss drug market. Fierce Healthcare. https://www.fiercehealthcare.com/health-tech/telehealth-companies-target-100b-weight-loss-drug-market-patients-grapple-access-costs 

Leo, L., & Mandowara, K. (2023, November 17). Boom in weight-loss drugs to drive up US employers’ medical costs ... Reuters. https://www.reuters.com/business/healthcare-pharmaceuticals/boom-weight-loss-drugs-drive-up-us-employers-medical-costs-2024-mercer-2023-11-17/ 

Mahase, E. (2024). GLP-1 agonist shortage will last until end of 2024, Government warns. BMJ. https://doi.org/10.1136/bmj.q28 
Mayo Foundation for Medical Education and Research. (2023, December 1). Semaglutide (subcutaneous route) proper use. Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/semaglutide-subcutaneous-route/proper-use/drg-20406730 

McCarthy, J. W., & Cretella, B. (2023, December 7). Availability of GLP-1 medications. Yale Health. https://yalehealth.yale.edu/story/availability-glp-1-medications 

Mounjaro: Uses, dosage, side effects & warnings. Drugs.com. (2024, January 10). https://www.drugs.com/mounjaro.html 

National Patient Safety Alert - DHSC. (2024, January 3). ViewAlert. Shortage of GLP-1 receptor agonists (GLP-1 RA) update. https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103245 

Ortaliza, J., Ortaliza, J., McGough, M., Salaga, M., Twitter, K. A., & Twitter, C. C. (2023, August 4). How much and why 2024 premiums are expected to grow in affordable care act marketplaces. Peterson-KFF Health System Tracker. https://www.healthsystemtracker.org/brief/how-much-and-why-2024-premiums-are-expected-to-grow-in-affordable-care-act-marketplaces/ 

Park, M. K. (2015). Handbook of Hormones. https://doi.org/10.1016/c2013-0-15395-0 

Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity. Pfizer. (2023, December 1). https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-topline-phase-2b-results-oral-glp-1r 

The science to obesity: WegovyTM (semaglutide) injection 2.4 mg. Wegovy. (2024a). https://www.wegovy.com/tools-and-resources/the-science-to-obesity.html 

Surampudi, V. (2023, January 12). Semaglutide, also known as Ozempic, for weight loss - what you need to know. UCLA Health. https://www.uclahealth.org/news/semaglutide-weight-loss-what-you-need-know

Thompson, J. (2023, November 8). FDA approves Lilly’s zepboundTM (tirzepatide) for Chronic Weight Management, a powerful new option for the treatment of obesity or overweight with weight-related medical problems. Eli Lilly and Company. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight 

Tucker, M. (2023, June 24). New oral GLP-1 agonist for obesity, type 2 diabetes. Medscape. https://www.medscape.com/viewarticle/993667?form=fpf 

Twitter, K. A., Twitter, K. A., Telesford, I., Twitter, R. S., & Twitter, C. C. (2023, August 17). How do prices of drugs for weight loss in the U.S. compare to peer nations’ prices? Peterson-KFF Health System Tracker. https://www.healthsystemtracker.org/brief/prices-of-drugs-for-weight-loss-in-the-us-and-peer-nations/ 

U.S. Department of Health and Human Services. (2021, September). Overweight & Obesity Statistics - Niddk. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity 

UC Davis Health. (2023, September 13). Ozempic for weight loss: Does it work, and what do experts recommend?. UC Davis Health. https://health.ucdavis.edu/blog/cultivating-health/ozempic-for-weight-loss-does-it-work-and-what-do-experts-recommend/2023/07 

United Nations. (2022, March 4). Over one billion obese people globally, health crisis must be reversed - who | UN news. United Nations. https://news.un.org/en/story/2022/03/1113312#:~:text=According%20to%20recent%20data%2C%20more,they%20are%20overweight%20or%20obese 

Wehrwein, P. (2023, March 28). For weight loss, off-label glp-1s are increasingly the chosen ones: AMCP 2023. Managed Healthcare Executive. https://www.managedhealthcareexecutive.com/view/for-weight-loss-the-glp-1s-are-the-ones-amcp-2023 

Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., Pratt, E., Kazda, C., & Konig, M. (2023). Daily Oral GLP-1 receptor agonist Orforglipron for adults with obesity. New England Journal of Medicine, 389(10), 877–888. https://doi.org/10.1056/nejmoa2302392 

Whitley, H. P., Trujillo, J. M., & Neumiller, J. J. (2023). Special report: Potential strategies for addressing GLP-1 and dual GLP-1/GIP receptor agonist shortages. Clinical Diabetes, 41(3), 467–473. https://doi.org/10.2337/cd23-0023 

Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183